Data-Driven Clinical Planning: Building Value-Added Data Assets

The increasing availability of public data sets offers a transformational opportunity for insight-driven planning at all phases of the drug development life cycle. Yet too often organizations adopt an ad hoc approach to data analysis rather than build data assets for both immediate and future use.

QuartzBio, part of Precision for Medicine’s Renee Deehan-Kenney and Tobi Guennel discuss opportunities to inform and accelerate critical drug development decisions with public data sets at all phases of the development lifecycle, and the steps necessary to move from ad hoc analyses to building a strategic asset.

Read the full article in Pharmaceutical Executive here

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics, adaptive clinical trial execution to regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.